Throughout the last three months, 4 analysts have evaluated Viatris (NASDAQ:VTRS), offering a diverse set of opinions from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts have recently evaluated Viatris and provided 12-month price targets. The average target is $10.75, accompanied by a high estimate of $14.00 and a low estimate of $9.00. This current average has decreased by 14.0% from the previous average price target of $12.50.

Decoding Analyst Ratings: A Detailed Look

The perception of Viatris by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Viatris's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Viatris analyst ratings.

All You Need to Know About Viatris

Financial Milestones: Viatris's Journey

Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.

Negative Revenue Trend: Examining Viatris's financials over 3 months reveals challenges. As of 31 December, 2024, the company experienced a decline of approximately -8.06% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Viatris's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -14.64%, the company may face hurdles in effective cost management.

Return on Equity (ROE): Viatris's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -2.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.

Return on Assets (ROA): Viatris's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.2%, the company may encounter challenges in delivering satisfactory returns from its assets.

Debt Management: Viatris's debt-to-equity ratio is below the industry average at 0.77, reflecting a lower dependency on debt financing and a more conservative financial approach.

Analyst Ratings: What Are They?

Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.

Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.

Which Stocks Are Analysts Recommending Now?

Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.

This article was generated by Benzinga's automated content engine and reviewed by an editor.